IRLAB Therapeutics - Looking beyond mesdopetam
IRLAB’s inaugural capital markets day outlined the depth of its expanding pipeline and the catalysts that will underpin share momentum over both the near and mid-term. Looking beyond its lead asset mesdopetam, pirepemat is increasingly coming into focus and the upcoming Phase IIb in Parkinson’s disease (PD) is expected to start imminently, enabling top-line data during H223. Progression of three preclinical assets (IRL942, IRL757 and P003) into the clinic can be expected throughout 2023, and will broaden the company’s therapeutic scope into new neurological disorders and indications outside PD. Mesdopetam ultimately remains the key, near-term value driver and top-line data from the Phase IIb/III PD-LIDs trial expected in H222 will define sentiment. We value IRLAB at SEK106/share.IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson's disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson's Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.